• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Odense University Hospital - Developmental Therapeutics Review - Q1 2011 Product Image

Odense University Hospital - Developmental Therapeutics Review - Q1 2011

  • Published: March 2011
  • 39 pages
  • Global Markets Direct

Odense University Hospital – Developmental Therapeutics Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Odense University Hospital – Developmental Therapeutics Review – Q1 2011” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by Odense University Hospital.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Odense University Hospital with READ MORE >



List of Tables
List of Figures
Odense University Hospital Snapshot
Odense University Hospital Overview
Key Information
Key Facts
Odense University Hospital – Research and Development Overview
Key Therapeutic Areas
Odense University Hospital – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Odense University Hospital – Pipeline Products Glance
Odense University Hospital – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Odense University Hospital Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Odense University Hospital – Drug Profiles
Candesartan
Product Description
Mechanism of Action
R&D Progress
Cholecalciferol
Product Description
Mechanism of Action
R&D Progress
Fluorouracil + Folinic Acid + Capecitabine
Product Description
Mechanism of Action
R&D Progress
Fosaprepitant dimeglumine + Dexamethasone + Palonosetron
Product Description
Mechanism of Action
R&D Progress
Marinol
Product Description
Mechanism of Action
R&D Progress
Oxaliplatin (Eloxatin) + Capecitabine (Xeloda)
Product Description
Mechanism of Action
R&D Progress
Spironolactone
Product Description
Mechanism of Action
R&D Progress
Cetuximab + Carboplatin + Vinorelbine
Product Description
Mechanism of Action
R&D Progress
FLOX + Erbitux
Product Description
Mechanism of Action
R&D Progress
Irinotecan + Cetuximab + Everolimus
Product Description
Mechanism of Action
R&D Progress
Navelbine + Radiation theraphy
Product Description
Mechanism of Action
R&D Progress
Navelbine + Radiotherapy
Product Description
Mechanism of Action
R&D Progress
Oxaliplatin + Capecitabine + Epirubicin
Product Description
Mechanism of Action
R&D Progress
Tarceva + Radiation theraphy
Product Description
Mechanism of Action
R&D Progress
XELOX
Product Description
Mechanism of Action
R&D Progress
Odense University Hospital – Pipeline Analysis
Odense University Hospital – Pipeline Products by Therapeutic Class
Odense University Hospital - Pipeline Products By Target
Odense University Hospital – Pipeline Products by Route of Administration
Odense University Hospital – Pipeline Products by Molecule Type
Odense University Hospital - Dormant Projects
Odense University Hospital – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Odense University Hospital Detailed Deal Summary
Asset Finance
Central Electric Power Completes Project Financing Of $20 Million For Transmission And Distribution Lines
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Site License The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.
Enterprisewide The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS

Our Clients

Our clients' logos